Rapamycin MimicsScarcity Signals but Leaves Epigenetic Noise Unchanged: A Test of the Impersonation Hypothesis

Hypothesis

Rapamycin extends lifespan by mimicking nutrient scarcity, but this impersonation leaves the underlying epigenetic noise and heterogeneity of aged cells unchanged, preserving a molecular 'memory' of prior damage.

Mechanistic Basis

While mTORC1 inhibition activates autophagy and suppresses SASP, it does not engage the chromatin remodelers that drive epigenetic resetting during true rejuvenation (e.g., OSK-mediated partial reprogramming). Rapamycin‑induced low‑energy signaling favors histone deacetylation via SIRT1 activation, leading to a compact but static heterochromatin that masks transcription of senescence genes without erasing age‑associated methylation drift or increasing nucleosome turnover. Consequently, the mean epigenetic age shifts downward, yet cell‑to‑cell variability and entropy remain high, reflecting persistent damage that rapamycin merely hides.

Predictions & Experimental Design

1. Epigenetic entropy will not decrease – Single‑cell methylome sequencing of liver from old mice treated with rapamycin for 3 months will show no reduction in Shannon entropy of CpG methylation compared to untreated aged controls, whereas partial reprogramming will lower entropy (1).
2. Transient heterochromatin marks increase – Rapamycin will elevate H3K9me3 and H3K27me3 levels globally, detectable by CUT&Tag, without a concomitant rise in H3K4me1 at enhancers that characterizes active chromatin remodeling (2).
3. Noise‑associated transcripts persist – RNA‑seq will reveal continued expression of stochastic, low‑abundance transcripts linked to DNA damage response, despite overall SASP suppression (3).
4. Synergy with true resetting agents – Combining rapamycin with a brief OSK pulse will additive‑ly reduce both mean epigenetic age and entropy, supporting the idea that rapamycin masks while OSK resets (4).
5. Functional readout correlates with noise – Mice showing persistent epigenetic entropy after rapamycin will exhibit delayed onset of frailty but no improvement in maximal lifespan, whereas entropy reduction correlates with extended maximal lifespan (5; 6).

Potential Outcomes & Interpretation

If rapamycin fails to lower epigenetic entropy while improving physiological readouts, the hypothesis that it impersonates a harder life without erasing aging memory gains support. Conversely, a detectable entropy decline would falsify the impersonation claim, suggesting rapamycin can drive genuine epigenetic rejuvenation under certain contexts.